BME MTF Equity Other Segments
24.80 mill. €
% Year 2021
ADL BIONATUR SOLUTIONS
AURIGA GLOBAL INVESTORS S.V., S.A.
IMPULSA CAPITAL S.L.
ERNST & YOUNG S.L.
AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA
Capital Admitted (thousands of euros)
Shares (x 1,000)
Period Close Price (euros)
Period Last Price (euros)
Period High Price (euros)
Period Low Price (euros)
Capitalisation (thousands of euros)
Volume (thousands of shares)
Turnover (thousands of euros)
ADL Bionatur is a biotechnology group strategically focused on the ‘One Health’ concept which encompasses human and animal health. Subsidiaries and a global commercial structure devoted to the monetisation of their different high-valued assets. Depending on their field of application, these assets can be categorised as follows: 1) detection / diagnosis, 2) prevention, 3) therapeutic, 4) fermentation ingredients. The Group's main strategy is to foster its commercial network in order to leverage the organic growth of its assets while evaluating opportunities of inorganic growth in the biotechnology field.
Resumen Discovery MeetingADL BIONATURForo Medcap 2019
Pilar de La Huerta, CEOADL BIONATURForo Medcap 2019
Pilar de la Huerta (CEO)ADL BIONATURMayo 2018
ADL BIONATUR SOLUTIONSDiscovery meeting(Foro Medcap 2018)
Entrevista Victor Infante -CEOBIONATURISForo Medcap 2017
Resumen discovery meeting (Foro Medcap - Junio 2017)BIONATURIS
Víctor Infante,Consejero DelegadoBIONATURIS
To obtain detailed information or information in other formats, please contact BME Market Data at
email@example.com or visit the website
The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at firstname.lastname@example.org.
Follow us in
What is BME Growth
News and Publications
Copyright © BME 2021. All rights reserved.